Protective effect of the G-765C COX-2 polymorphism on subclinical atherosclerosis and inflammatory markers in asymptomatic subjects with cardiovascular risk factors.

[1]  W. Barker,et al.  The cyclooxygenase 2 -765 C promoter allele is a protective factor for Alzheimer's disease , 2006, Neuroscience Letters.

[2]  J. Paramo,et al.  Monocyte cyclooxygenase-2 activity: a new therapeutic target for atherosclerosis? , 2005, Current drug targets. Cardiovascular & haematological disorders.

[3]  J. Paramo,et al.  Independent association of von Willebrand factor with surrogate markers of atherosclerosis in middle‐aged asymptomatic subjects , 2005, Journal of thrombosis and haemostasis : JTH.

[4]  G. Norata,et al.  Native LDL and oxidized LDL modulate cyclooxygenase-2 expression in HUVECs through a p38-MAPK, NF-kappaB, CRE dependent pathway and affect PGE2 synthesis. , 2004, International journal of molecular medicine.

[5]  G. Dagenais,et al.  Impact of Prolonged Cyclooxygenase-2 Inhibition on Inflammatory Markers and Endothelial Function in Patients With Ischemic Heart Disease and Raised C-Reactive Protein: A Randomized Placebo-Controlled Study , 2004, Circulation.

[6]  B. Dahlöf,et al.  Surrogate markers for cardiovascular disease: structural markers. , 2004, Circulation.

[7]  S. Martinotti,et al.  A polymorphism in the cyclooxygenase 2 gene as an inherited protective factor against myocardial infarction and stroke. , 2004, JAMA.

[8]  J. Paramo,et al.  Prothrombin Fragment 1+2 Is Associated With Carotid Intima-Media Thickness in Subjects Free of Clinical Cardiovascular Disease , 2004, Stroke.

[9]  D. Tzivoni,et al.  Rofecoxib, a COX-2 inhibitor, lowers C-reactive protein and interleukin-6 levels in patients with acute coronary syndromes. , 2004, Chest.

[10]  M. Linton,et al.  Cyclooxygenase-2 and inflammation in atherosclerosis. , 2004, Current opinion in pharmacology.

[11]  R. Muraro,et al.  Suppression of the Functionally Coupled Cyclooxygenase-2/Prostaglandin E Synthase as a Basis of Simvastatin-Dependent Plaque Stabilization in Humans , 2003, Circulation.

[12]  S. Humphries,et al.  Common Promoter Variant in Cyclooxygenase-2 Represses Gene Expression: Evidence of Role in Acute-Phase Inflammatory Response , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[13]  T. Tanabe,et al.  Cyclooxygenase isozymes and their gene structures and expression. , 2002, Prostaglandins & other lipid mediators.

[14]  I. Morita.  Distinct functions of COX-1 and COX-2. , 2002, Prostaglandins & other lipid mediators.

[15]  J. Morrow,et al.  Cyclooxygenase-2–Dependent Prostacyclin Formation Is Regulated by Low Density Lipoprotein Cholesterol In Vitro , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[16]  P. Libby,et al.  Inflammation and Atherosclerosis , 2002, Circulation.

[17]  D. Pisetsky,et al.  Progress in the treatment of rheumatoid arthritis. , 2001, JAMA.

[18]  E. Hawe,et al.  The interleukin-6 -174 G/C promoter polymorphism is associated with risk of coronary heart disease and systolic blood pressure in healthy men. , 2001, European heart journal.

[19]  D. Bell,et al.  Functional characterization of cyclooxygenase-2 polymorphisms. , 2001, The Journal of pharmacology and experimental therapeutics.

[20]  F. Cipollone,et al.  Overexpression of Functionally Coupled Cyclooxygenase-2 and Prostaglandin E Synthase in Symptomatic Atherosclerotic Plaques as a Basis of Prostaglandin E2-Dependent Plaque Instability , 2001, Circulation.

[21]  R. Langenbach,et al.  Why there are two cyclooxygenase isozymes. , 2001, The Journal of clinical investigation.

[22]  K. Yamagata,et al.  Coexpression of Microsomal-Type Prostaglandin E Synthase with Cyclooxygenase-2 in Brain Endothelial Cells of Rats during Endotoxin-Induced Fever , 2001, The Journal of Neuroscience.

[23]  R. Bolli,et al.  Cyclooxygenase-2 mediates the cardioprotective effects of the late phase of ischemic preconditioning in conscious rabbits. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[24]  F. Fitzpatrick,et al.  Cyclooxygenase-2 and carcinogenesis. , 2000, Biochimica et biophysica acta.

[25]  P. Libby,et al.  Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. , 1999, The American journal of pathology.

[26]  D. Gilroy,et al.  Inducible cyclooxygenase may have anti-inflammatory properties , 1999, Nature Medicine.

[27]  R. Hall,et al.  Cyclooxygenase-2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalizes with inducible nitric oxide synthase and nitrotyrosine particularly in macrophages. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[28]  Sharon R. Adderley,et al.  Oxidative Damage of Cardiomyocytes Is Limited by Extracellular Regulated Kinases 1/2-mediated Induction of Cyclooxygenase-2* , 1999, The Journal of Biological Chemistry.

[29]  E. Shacter,et al.  Regulation of Macrophage Cytokine Production by Prostaglandin E2 , 1997, The Journal of Biological Chemistry.

[30]  A. Folsom,et al.  Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 1987-1993. , 1997, American journal of epidemiology.

[31]  N. Goldman,et al.  Regulation of human C-reactive protein gene expression by two synergistic IL-6 responsive elements. , 1996, Biochemistry.

[32]  J. Paramo,et al.  Monocyte cyclooxygenase-2 overactivity: a new marker of subclinical atherosclerosis in asymptomatic subjects with cardiovascular risk factors? , 2005, European heart journal.

[33]  R. DuBois,et al.  Cyclooxygenase-2: a therapeutic target. , 2002, Annual review of medicine.

[34]  J. Vane,et al.  Cyclooxygenases 1 and 2. , 1998, Annual review of pharmacology and toxicology.